Drug profile · INN
daratumumab and hyaluronidase-fihj
DARZALEX FASPRO
daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Drug details — daratumumab and hyaluronidase-fihj
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is daratumumab and hyaluronidase-fihj?
daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daratumumab and hyaluronidase-fihj?
DARZALEX FASPRO is a marketed brand name for daratumumab and hyaluronidase-fihj. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daratumumab and hyaluronidase-fihj?
daratumumab and hyaluronidase-fihj has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.